Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

by John O. Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M. Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Coughlin, Elliott Winton, Timothy C. Burn, Peter O’Neill, Jason Clark, Deborah Hunter, Albert Assad, Ronald Hoffman, Srdan Verstovsek
Published 2017-02-01